418 related articles for article (PubMed ID: 30046162)
1. Subclonal evolution in disease progression from MGUS/SMM to multiple myeloma is characterised by clonal stability.
Dutta AK; Fink JL; Grady JP; Morgan GJ; Mullighan CG; To LB; Hewett DR; Zannettino ACW
Leukemia; 2019 Feb; 33(2):457-468. PubMed ID: 30046162
[TBL] [Abstract][Full Text] [Related]
2. Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms.
Walker BA; Wardell CP; Melchor L; Brioli A; Johnson DC; Kaiser MF; Mirabella F; Lopez-Corral L; Humphray S; Murray L; Ross M; Bentley D; Gutiérrez NC; Garcia-Sanz R; San Miguel J; Davies FE; Gonzalez D; Morgan GJ
Leukemia; 2014 Feb; 28(2):384-390. PubMed ID: 23817176
[TBL] [Abstract][Full Text] [Related]
3. From MGUS to Multiple Myeloma, a Paradigm for Clonal Evolution of Premalignant Cells.
van Nieuwenhuijzen N; Spaan I; Raymakers R; Peperzak V
Cancer Res; 2018 May; 78(10):2449-2456. PubMed ID: 29703720
[TBL] [Abstract][Full Text] [Related]
4. Single-cell profiling of tumour evolution in multiple myeloma - opportunities for precision medicine.
Dutta AK; Alberge JB; Sklavenitis-Pistofidis R; Lightbody ED; Getz G; Ghobrial IM
Nat Rev Clin Oncol; 2022 Apr; 19(4):223-236. PubMed ID: 35017721
[TBL] [Abstract][Full Text] [Related]
5. Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).
Ho M; Patel A; Goh CY; Moscvin M; Zhang L; Bianchi G
Leukemia; 2020 Dec; 34(12):3111-3125. PubMed ID: 33046818
[TBL] [Abstract][Full Text] [Related]
6. Molecular and biologic markers of progression in monoclonal gammopathy of undetermined significance to multiple myeloma.
Mailankody S; Mena E; Yuan CM; Balakumaran A; Kuehl WM; Landgren O
Leuk Lymphoma; 2010 Dec; 51(12):2159-70. PubMed ID: 20958231
[TBL] [Abstract][Full Text] [Related]
7. Gene Expression Analysis of the Bone Marrow Microenvironment Reveals Distinct Immunotypes in Smoldering Multiple Myeloma Associated to Progression to Symptomatic Disease.
Isola I; Brasó-Maristany F; Moreno DF; Mena MP; Oliver-Calders A; Paré L; Rodríguez-Lobato LG; Martin-Antonio B; Cibeira MT; Bladé J; Rosiñol L; Prat A; Lozano E; Fernández de Larrea C
Front Immunol; 2021; 12():792609. PubMed ID: 34880879
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Kyle RA; Rajkumar SV
Curr Hematol Malig Rep; 2010 Apr; 5(2):62-9. PubMed ID: 20425398
[TBL] [Abstract][Full Text] [Related]
9. The diagnostic value of SE MRI and DWI of the spine in patients with monoclonal gammopathy of undetermined significance, smouldering myeloma and multiple myeloma.
Dutoit JC; Vanderkerken MA; Anthonissen J; Dochy F; Verstraete KL
Eur Radiol; 2014 Nov; 24(11):2754-65. PubMed ID: 25106487
[TBL] [Abstract][Full Text] [Related]
10. The effects of short-term, progressive exercise training on disease activity in smouldering multiple myeloma and monoclonal gammopathy of undetermined significance: a single-arm pilot study.
Emery A; Moore S; Crowe J; Murray J; Peacock O; Thompson D; Betts F; Rapps S; Ross L; Rothschild-Rodriguez D; Arana Echarri A; Davies R; Lewis R; Augustine DX; Whiteway A; Afzal Z; Heaney J; Drayson MT; Turner JE; Campbell JP
BMC Cancer; 2024 Feb; 24(1):174. PubMed ID: 38317104
[TBL] [Abstract][Full Text] [Related]
11. A contribution to examination of propidium iodide and annexin V plasma cells indices in multiple myeloma.
Scudla V; Ordeltova M; Bacovsky J; Vytrasova M; Sumna E; Martinek A; Horak P
Neoplasma; 2003; 50(5):363-71. PubMed ID: 14628090
[TBL] [Abstract][Full Text] [Related]
12. Prevention of progression in monoclonal gammopathy of undetermined significance.
Rajkumar SV
Clin Cancer Res; 2009 Sep; 15(18):5606-8. PubMed ID: 19737944
[TBL] [Abstract][Full Text] [Related]
13. Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells.
Pérez-Persona E; Mateo G; García-Sanz R; Mateos MV; de Las Heras N; de Coca AG; Hernández JM; Galende J; Martín-Nuñez G; Bárez A; Alonso JM; Martín A; López-Berges C; Orfao A; San Miguel JF; Vidriales MB
Br J Haematol; 2010 Jan; 148(1):110-4. PubMed ID: 19821821
[TBL] [Abstract][Full Text] [Related]
14. Multiple myeloma.
van de Donk NWCJ; Pawlyn C; Yong KL
Lancet; 2021 Jan; 397(10272):410-427. PubMed ID: 33516340
[TBL] [Abstract][Full Text] [Related]
15. A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS/SMM to newly diagnosed and relapsed multiple myeloma.
Oliva S; De Paoli L; Ruggeri M; Caltagirone S; Troia R; Oddolo D; D'Agostino M; Gilestro M; Mina R; Saraci E; Margiotta Casaluci G; Genuardi E; Bringhen S; Boccadoro M; Omedé P
Ann Hematol; 2021 Feb; 100(2):437-443. PubMed ID: 33392702
[TBL] [Abstract][Full Text] [Related]
16. MGUS and Smoldering Multiple Myeloma: Diagnosis and Epidemiology.
Mateos MV; Landgren O
Cancer Treat Res; 2016; 169():3-12. PubMed ID: 27696254
[TBL] [Abstract][Full Text] [Related]
17. Addition of Rice Bran Arabinoxylan to Curcumin Therapy May Be of Benefit to Patients With Early-Stage B-Cell Lymphoid Malignancies (Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Stage 0/1 Chronic Lymphocytic Leukemia): A Preliminary Clinical Study.
Golombick T; Diamond TH; Manoharan A; Ramakrishna R
Integr Cancer Ther; 2016 Jun; 15(2):183-9. PubMed ID: 27154182
[TBL] [Abstract][Full Text] [Related]
18. Genome-wide association study of monoclonal gammopathy of unknown significance (MGUS): comparison with multiple myeloma.
Thomsen H; Chattopadhyay S; Weinhold N; Vodicka P; Vodickova L; Hoffmann P; Nöthen MM; Jöckel KH; Langer C; Hajek R; Hallmans G; Pettersson-Kymmer U; Ohlsson C; Späth F; Houlston R; Goldschmidt H; Hemminki K; Försti A
Leukemia; 2019 Jul; 33(7):1817-1821. PubMed ID: 30737484
[No Abstract] [Full Text] [Related]
19. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Cesana C; Klersy C; Barbarano L; Nosari AM; Crugnola M; Pungolino E; Gargantini L; Granata S; Valentini M; Morra E
J Clin Oncol; 2002 Mar; 20(6):1625-34. PubMed ID: 11896113
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Biomarkers in the Progression From MGUS to Multiple Myeloma: A Systematic Review.
Cosemans C; Oben B; Arijs I; Daniëls A; Declercq J; Vanhees K; Froyen G; Maes B; Mebis J; Rummens JL
Clin Lymphoma Myeloma Leuk; 2018 Apr; 18(4):235-248. PubMed ID: 29506935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
